Fresenius opens the week with sector pressure, shares trade lower on Xetra
Published on 06/22/2026 at 16:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-22, 16:13.
Fresenius (DE0005785604) starts the week in the DAX health-care cohort with its shares trading around the high-30-euro range on Xetra, reflecting mild weakness against the broader index. Sector news around German hospitals and the latest analyst view from Deutsche Bank frame the discussion for the stock today.
What Reuters and peers report
The German hospital landscape remains under structural pressure, with the German Hospital Federation warning that roughly half of clinics could face insolvency without reforms, according to a recent newswire summary of sector commentary. MarketScreener aggregates the related Deutsche Presse-Agentur report, underscoring the challenging backdrop for private and public operators alike.
Fresenius, via its Helios hospital arm, is directly exposed to this environment and competes in Germany with listed peers such as Rhön-Klinikum and international operators including Ramsay Santé. As a DAX and Stoxx Europe 600 member, the group’s performance in the hospital and broader health-care services space feeds into European sector indices watched by institutional investors.
Analyst stance and recent trading
On the analyst side, Deutsche Bank most recently reiterated its "Buy" rating on Fresenius with a price target of 55 euros in a mid-June update, according to an overview of broker opinions. The MarketScreener analyst summary shows a predominantly positive stance, with a majority of recommendations in the Buy or Outperform range.
In Monday morning Xetra trade, Fresenius shares ticked lower by about 0.6 percent to 39.39 euros at 09:06 CET, with an intraday low at 39.31 euros, as reported by a real-time market comment. Finanzen.net highlights the stock as one of the weaker names in the session, even though the absolute move remains moderate in the context of typical daily volatility.
Background and price data on Fresenius
Key figures, news and historical performance for the Fresenius shares can be found in the dedicated topic area and on the company’s investor-relations pages.
The business behind Fresenius
Fresenius generates revenue across four main pillars: Helios hospitals, Kabi injectable drugs and clinical nutrition, Vamed health-care projects and services, and a stake in dialysis specialist Fresenius Medical Care. The group focuses on acute and chronic patient care, from operating German hospitals to supplying infusion therapies globally.
Where the Fresenius shares trade
The Fresenius shares (DE0005785604) last traded on Xetra at 39.39 euros as of 2026-06-22, 09:06 CET, based on intraday data from German trading platforms.
Key data on the Fresenius shares
- Company: Fresenius SE & Co. KGaA
- ISIN: DE0005785604
- WKN: 578560
- Ticker: FRE
- Trading venue: Xetra
- Price (as of 2026-06-22, 09:06): 39.39 EUR
- Market cap: around 22 billion EUR (as of 2026-06-22)
- Sector / industry: Health-care services
- Index membership: DAX, Stoxx Europe 600
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. Historical performance is not a reliable indicator of future results.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
